BioSpace News Archive

The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, is expanding its operations with the appointment of three senior-level staff.

ABIONYX Pharma is pleased to announce the appointment of Dr. Rob Scott as Chief Medical Officer and Head of R&D with immediate effect.

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2023.

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Robert Mashal, M.D. to its Board of Directors.

RTI Surgical announced that it has signed a definitive agreement to acquire Cook Biotech Incorporated, a leader in advanced tissue-repair products from biomaterials, headquartered in West Lafayette, Indiana.

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S (Nasdaq: ASND) for its endocrinology portfolio.

Astellas Pharma Inc. announced the U.S. Food and Drug Administration issued a complete response letter on January 4, 2024, regarding the Biologics License Application for zolbetuximab, an investigational agent for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.

AIDS Healthcare Foundation sent an open letter to the heads of the Joint United Nations Programme on HIV/AIDS and the World Health Organization, urging the two institutions to conduct an audit of their HIV data over concerns that the global number of people on HIV treatment is overstated significantly.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces that the first Phase 3 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with overweight or obesity (GLORY-1) met the primary endpoints and all key secondary endpoints.